View in EDS

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial.

Saved in:
Bibliographic Details
Title: Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial.
Authors: Niemann CU; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Dubois J; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Nasserinejad K; Hovon Foundation, Erasmus MC University Medical Center, Rotterdam, The Netherlands., da Cunha-Bang C; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Kersting S; Department of Hematology, HagaZiekenhuis, Den Haag, The Netherlands., Enggaard L; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Veldhuis GJ; Department of Hematology, Antonius Ziekenhuis, Sneek, The Netherlands., Mous R; Department of Hematology, Universitair Medisch Centrum Utrecht, Utrecht, The Netherlands., Mellink CHM; Department of Human Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., van der Kevie-Kersemaekers AF; Department of Clinical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands., Dobber JA; Laboratory of Special Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Poulsen CB; Department of Hematology, Zealand University Hospital, Roskilde, Denmark., Razawy W; Hovon Foundation, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Hollestein R; Hovon Foundation, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Frederiksen H; Department of Hematology, Odense University Hospital, Odense, Denmark., Janssens A; Department of Hematology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium., Schjødt I; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Dompeling EC; Department of Hematology, Isala Ziekenhuis, Zwolle, The Netherlands., Ranti J; Department of Hematology, Turku University Central Hospital, Turku, Finland., Brieghel C; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Mattsson M; Department of Hematology, Uppsala University Hospital, Uppsala, Sweden., Bellido M; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Tran HTT; Department of Hematology, Akershus University Hospital, Lørenskog, Norway., Kater AP; Hovon Foundation, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Levin MD; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
Source: Blood advances [Blood Adv] 2025 Aug 12; Vol. 9 (15), pp. 3665-3675.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40249856
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Niemann+CU%22">Niemann CU</searchLink>; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Dubois+J%22">Dubois J</searchLink>; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Nasserinejad+K%22">Nasserinejad K</searchLink>; Hovon Foundation, Erasmus MC University Medical Center, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22da+Cunha-Bang+C%22">da Cunha-Bang C</searchLink>; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Kersting+S%22">Kersting S</searchLink>; Department of Hematology, HagaZiekenhuis, Den Haag, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Enggaard+L%22">Enggaard L</searchLink>; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Veldhuis+GJ%22">Veldhuis GJ</searchLink>; Department of Hematology, Antonius Ziekenhuis, Sneek, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Mous+R%22">Mous R</searchLink>; Department of Hematology, Universitair Medisch Centrum Utrecht, Utrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Mellink+CHM%22">Mellink CHM</searchLink>; Department of Human Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+der+Kevie-Kersemaekers+AF%22">van der Kevie-Kersemaekers AF</searchLink>; Department of Clinical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Dobber+JA%22">Dobber JA</searchLink>; Laboratory of Special Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Poulsen+CB%22">Poulsen CB</searchLink>; Department of Hematology, Zealand University Hospital, Roskilde, Denmark.<br /><searchLink fieldCode="AU" term="%22Razawy+W%22">Razawy W</searchLink>; Hovon Foundation, Erasmus MC University Medical Center, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Hollestein+R%22">Hollestein R</searchLink>; Hovon Foundation, Erasmus MC University Medical Center, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Frederiksen+H%22">Frederiksen H</searchLink>; Department of Hematology, Odense University Hospital, Odense, Denmark.<br /><searchLink fieldCode="AU" term="%22Janssens+A%22">Janssens A</searchLink>; Department of Hematology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Schjødt+I%22">Schjødt I</searchLink>; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Dompeling+EC%22">Dompeling EC</searchLink>; Department of Hematology, Isala Ziekenhuis, Zwolle, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Ranti+J%22">Ranti J</searchLink>; Department of Hematology, Turku University Central Hospital, Turku, Finland.<br /><searchLink fieldCode="AU" term="%22Brieghel+C%22">Brieghel C</searchLink>; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Mattsson+M%22">Mattsson M</searchLink>; Department of Hematology, Uppsala University Hospital, Uppsala, Sweden.<br /><searchLink fieldCode="AU" term="%22Bellido+M%22">Bellido M</searchLink>; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Tran+HTT%22">Tran HTT</searchLink>; Department of Hematology, Akershus University Hospital, Lørenskog, Norway.<br /><searchLink fieldCode="AU" term="%22Kater+AP%22">Kater AP</searchLink>; Hovon Foundation, Erasmus MC University Medical Center, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Levin+MD%22">Levin MD</searchLink>; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101698425%22">Blood advances</searchLink> [Blood Adv] 2025 Aug 12; Vol. 9 (15), pp. 3665-3675.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Hematology%22">American Society of Hematology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101698425 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-9537 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224739529%22">24739529 </searchLink><i>NLM ISO Abbreviation: </i>Blood Adv <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40249856
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/bloodadvances.2024015180
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3665
    Titles:
      – TitleFull: Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Niemann CU
      – PersonEntity:
          Name:
            NameFull: Dubois J
      – PersonEntity:
          Name:
            NameFull: Nasserinejad K
      – PersonEntity:
          Name:
            NameFull: da Cunha-Bang C
      – PersonEntity:
          Name:
            NameFull: Kersting S
      – PersonEntity:
          Name:
            NameFull: Enggaard L
      – PersonEntity:
          Name:
            NameFull: Veldhuis GJ
      – PersonEntity:
          Name:
            NameFull: Mous R
      – PersonEntity:
          Name:
            NameFull: Mellink CHM
      – PersonEntity:
          Name:
            NameFull: van der Kevie-Kersemaekers AF
      – PersonEntity:
          Name:
            NameFull: Dobber JA
      – PersonEntity:
          Name:
            NameFull: Poulsen CB
      – PersonEntity:
          Name:
            NameFull: Razawy W
      – PersonEntity:
          Name:
            NameFull: Hollestein R
      – PersonEntity:
          Name:
            NameFull: Frederiksen H
      – PersonEntity:
          Name:
            NameFull: Janssens A
      – PersonEntity:
          Name:
            NameFull: Schjødt I
      – PersonEntity:
          Name:
            NameFull: Dompeling EC
      – PersonEntity:
          Name:
            NameFull: Ranti J
      – PersonEntity:
          Name:
            NameFull: Brieghel C
      – PersonEntity:
          Name:
            NameFull: Mattsson M
      – PersonEntity:
          Name:
            NameFull: Bellido M
      – PersonEntity:
          Name:
            NameFull: Tran HTT
      – PersonEntity:
          Name:
            NameFull: Kater AP
      – PersonEntity:
          Name:
            NameFull: Levin MD
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 12
              M: 08
              Text: 2025 Aug 12
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2473-9537
          Numbering:
            – Type: volume
              Value: 9
            – Type: issue
              Value: 15
          Titles:
            – TitleFull: Blood advances
              Type: main
ResultId 1